Oct 03, 2022

Researchers claim that they conducted a Phase I trial to assess the efficacy and safety of paclitaxel, sapanisertib, and serabelisib. This was an open-label cohort trial comparing sapanisertib (TAK-22...

Oct 03, 2022

According to researchers, a patient's understanding of surgery is often limited in the context of sophisticated oncologic operations. Supplemental materials can help patients learn more about their su...

Oct 03, 2022

Recurrent ovarian cancer (rOC) responds well to anti-angiogenic therapy with bevacizumab in combination with chemotherapy; however, information on tyrosine kinase inhibitors following progression on m...

Oct 03, 2022

The purpose of researchers was to determine if gynecologic cancer patients who undergo surgery have a higher risk of postoperative problems, readmissions, or discharge locations other than a home usin...

Oct 03, 2022

To investigate the relative contributions of individual insurance status and hospital payer mix (safety net status) to quality of care and survival for patients with cervical cancer. Researchers used ...

Sep 15, 2022

Patients with recurrent cervical or endometrial cancer were included in this study to evaluate the safety and efficacy of combination bevacizumab rucaparib treatment. About 33 individuals were enrolle...

Sep 15, 2022

The goal of this study was to determine if the effectiveness of first-line maintenance therapy with niraparib differs among patients with newly diagnosed advanced ovarian cancer based on the timing of...

Sep 15, 2022

The purpose of this study is to determine whether or not substantial postoperative problems have a negative effect on survival for patients with advanced ovarian cancer who have undergone cytoreductiv...

Sep 15, 2022

The aggressive endometrial cancer subtype known as uterine serous carcinoma (USC) has a dismal survival rate. In advanced/recurrent HER2/neu-positive USC, trastuzumab is a known target because approxi...

Sep 15, 2022

Historically, Lynch syndrome genes or PTEN have been linked to hereditary uterine cancer (UC); however, there is mounting evidence that other genes have a role and may offer novel clinical therapy opt...

Sep 15, 2022

A substantial death rate is linked to high-grade serous ovarian cancer (HGSOC), the most frequent subtype of ovarian cancer. Surgical success or failure is a major indicator of long-term health. Prese...

Sep 15, 2022

It has recently come to light that the epigenetic alteration of adenosine to inosine (A-to-I) RNA editing is a critical carcinogenic process in human malignancies. Its clinical importance and function...

Sep 15, 2022

It is still unclear what the best adjuvant treatment for uterine leiomyosarcoma (uLMS) is. Researchers assessed the rate at which stage II and stage III uLMS patients received adjuvant chemotherapy an...

Sep 14, 2022

For a study, researchers sought to determine whether or not women who have been diagnosed with cervical cancer had a higher risk of using hypnotics, and we also found risk indicators for persistent us...

Sep 14, 2022

Cervical cancer in FIGO stage IVA is rare and carries a dismal prognosis. Overall survival (OS) in these patients is low despite the use of PET/CT for staging, concomitant treatment, and image-guided ...

Sep 14, 2022

For a study, researchers sought to evaluate the accuracy of human epididymis protein 4 (HE4) in distinguishing benign or borderline from malignant tumors in patients presenting to general hospitals wi...

Sep 14, 2022

In recent years, sentinel node mapping (SNM) has become increasingly popular as a treatment for clinically evident early-stage endometrial cancer (EC). Here, researchers looked at and examined how wel...

Sep 14, 2022

One of the proposed quality metrics for patients with epithelial ovarian cancer  (EOC) is the provision of adjuvant chemotherapy within 42 days of surgery. The purpose of this research was to determi...

Sep 14, 2022

Patients with recurrent ovarian cancer (ROC) can evaluate the efficacy and safety of palliative chemotherapy by using the Measure of Ovarian Symptoms and Treatment (MOST) concerns; a validated patient...

Sep 14, 2022

In the multicohort phase 2 KEYNOTE-158 study, pembrolizumab showed an objective response rate clinically significant in patients with advanced MSI-H/dMMR endometrial cancer who had had prior treatment...